CL2008001848A1 - Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. - Google Patents
Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal.Info
- Publication number
- CL2008001848A1 CL2008001848A1 CL2008001848A CL2008001848A CL2008001848A1 CL 2008001848 A1 CL2008001848 A1 CL 2008001848A1 CL 2008001848 A CL2008001848 A CL 2008001848A CL 2008001848 A CL2008001848 A CL 2008001848A CL 2008001848 A1 CL2008001848 A1 CL 2008001848A1
- Authority
- CL
- Chile
- Prior art keywords
- benzodiazepine
- combination
- chemotherapeutic agent
- peeeeeeeequenas
- imidazolo
- Prior art date
Links
- 239000002246 antineoplastic agent Substances 0.000 title abstract 2
- 229940127089 cytotoxic agent Drugs 0.000 title abstract 2
- HRJWTAWVFDCTGO-UHFFFAOYSA-N LY-2090314 Chemical compound C1CN(C=23)C=C(C=4C(NC(=O)C=4C=4N5C=CC=CC5=NC=4)=O)C3=CC(F)=CC=2CN1C(=O)N1CCCCC1 HRJWTAWVFDCTGO-UHFFFAOYSA-N 0.000 title 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 title 1
- 201000005202 lung cancer Diseases 0.000 title 1
- 208000020816 lung neoplasm Diseases 0.000 title 1
- 230000002611 ovarian Effects 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- SVUOLADPCWQTTE-UHFFFAOYSA-N 1h-1,2-benzodiazepine Chemical compound N1N=CC=CC2=CC=CC=C12 SVUOLADPCWQTTE-UHFFFAOYSA-N 0.000 abstract 1
- 206010009944 Colon cancer Diseases 0.000 abstract 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 206010033128 Ovarian cancer Diseases 0.000 abstract 1
- 206010061535 Ovarian neoplasm Diseases 0.000 abstract 1
- 229940049706 benzodiazepine Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 229960004679 doxorubicin Drugs 0.000 abstract 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 abstract 1
- 229960005420 etoposide Drugs 0.000 abstract 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 abstract 1
- 229960005277 gemcitabine Drugs 0.000 abstract 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 1
- QOFFJEBXNKRSPX-ZDUSSCGKSA-N pemetrexed Chemical compound C1=N[C]2NC(N)=NC(=O)C2=C1CCC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 QOFFJEBXNKRSPX-ZDUSSCGKSA-N 0.000 abstract 1
- 229960005079 pemetrexed Drugs 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/724—Cyclodextrins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/243—Platinum; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Steroid Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94751207P | 2007-07-02 | 2007-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2008001848A1 true CL2008001848A1 (es) | 2009-05-29 |
Family
ID=39737054
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2008001848A CL2008001848A1 (es) | 2007-07-02 | 2008-06-20 | Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. |
| CL2011003046A CL2011003046A1 (es) | 2007-07-02 | 2011-12-02 | Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08). |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2011003046A CL2011003046A1 (es) | 2007-07-02 | 2011-12-02 | Composicion farmaceutica que comprende 7-(2,5-dihidro-4-imidazo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk] [1,4]benzodiazepina, una sal o solvato, sbe7-b-cd y opcionalmente un tampon; proceso de preparacion; util para tratar cancer (div. sol. 1848-08). |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US8318713B2 (OSRAM) |
| EP (1) | EP2173348B1 (OSRAM) |
| JP (2) | JP5551589B2 (OSRAM) |
| KR (1) | KR101230085B1 (OSRAM) |
| CN (2) | CN102772416A (OSRAM) |
| AR (1) | AR067112A1 (OSRAM) |
| AU (1) | AU2008270732B2 (OSRAM) |
| BR (1) | BRPI0813789A2 (OSRAM) |
| CA (1) | CA2691587C (OSRAM) |
| CL (2) | CL2008001848A1 (OSRAM) |
| EA (2) | EA023697B1 (OSRAM) |
| ES (1) | ES2561202T3 (OSRAM) |
| IL (2) | IL202237A (OSRAM) |
| MA (1) | MA31677B1 (OSRAM) |
| MX (1) | MX2009013449A (OSRAM) |
| MY (1) | MY154472A (OSRAM) |
| NZ (1) | NZ581355A (OSRAM) |
| PE (1) | PE20090838A1 (OSRAM) |
| TW (1) | TWI428132B (OSRAM) |
| UA (1) | UA97400C2 (OSRAM) |
| WO (1) | WO2009006043A2 (OSRAM) |
| ZA (1) | ZA200908725B (OSRAM) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
| SG175207A1 (en) * | 2009-04-14 | 2011-11-28 | Lilly Co Eli | Benzodiazepine derivative for the treatment of hematopoietic neoplasm and leukemia |
| US20150017245A1 (en) * | 2011-09-22 | 2015-01-15 | Bind Therapeutics, Inc. | Methods of treating cancers with therapeutic nanoparticles |
| TW201417817A (zh) * | 2012-09-25 | 2014-05-16 | Daiichi Sankyo Co Ltd | Ｇｓｋ３抑制劑與抗ｄｒ５抗體之組合 |
| WO2016175324A1 (ja) * | 2015-04-30 | 2016-11-03 | 大鵬薬品工業株式会社 | 抗腫瘍剤の副作用軽減剤 |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10016507B2 (en) * | 2016-03-02 | 2018-07-10 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: III |
| US10213511B2 (en) * | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US11066419B2 (en) * | 2016-12-30 | 2021-07-20 | Frequency Therapeutics, Inc. | 1H-pyrrole-2,5-dione compounds and methods of using same |
| EP3920885A1 (en) | 2019-02-08 | 2021-12-15 | Frequency Therapeutics, Inc. | Valproic acid compounds and wnt agonists for treating ear disorders |
| WO2022256656A1 (en) * | 2021-06-03 | 2022-12-08 | University Of Cincinnati | Bzd-1 as a chemosensitizer of cancer |
| CN113956157B (zh) * | 2021-11-18 | 2024-05-03 | 西安都创医药科技有限公司 | 一种合成2-甲酰基-1-环丙烷甲酸乙酯的方法 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8904161D0 (en) | 1989-02-23 | 1989-04-05 | Hoffmann La Roche | Substituted pyrroles |
| US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
| KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
| EP1788086A1 (en) * | 1997-03-17 | 2007-05-23 | Human Genome Sciences, Inc. | Death Domain Containing Receptor 5 |
| US7034013B2 (en) | 2001-03-20 | 2006-04-25 | Cydex, Inc. | Formulations containing propofol and a sulfoalkyl ether cyclodextrin |
| CN1312154C (zh) * | 2002-03-05 | 2007-04-25 | 伊莱利利公司 | 作为激酶抑制剂的嘌呤衍生物 |
| EP1539756B1 (en) | 2002-09-19 | 2007-11-14 | Schering Corporation | Imidazopyridines as cyclin dependent kinase inhibitors |
| CN1980681A (zh) * | 2004-07-09 | 2007-06-13 | 新加坡科技研究局 | GSK－3β的调节及治疗增殖性病变的方法 |
| GB0418328D0 (en) * | 2004-08-17 | 2004-09-22 | Imp College Innovations Ltd | Cancer methods and medicaments |
| US20060252082A1 (en) * | 2005-05-04 | 2006-11-09 | University Of South Florida | Predicting treatment response in cancer subjects |
| TWI428132B (zh) * | 2007-07-02 | 2014-03-01 | Lilly Co Eli | 癌症化療效果之強化 |
-
2008
- 2008-06-18 TW TW097122720A patent/TWI428132B/zh not_active IP Right Cessation
- 2008-06-19 PE PE2008001054A patent/PE20090838A1/es not_active Application Discontinuation
- 2008-06-20 MX MX2009013449A patent/MX2009013449A/es active IP Right Grant
- 2008-06-20 CL CL2008001848A patent/CL2008001848A1/es unknown
- 2008-06-20 AU AU2008270732A patent/AU2008270732B2/en not_active Ceased
- 2008-06-20 NZ NZ581355A patent/NZ581355A/en not_active IP Right Cessation
- 2008-06-20 UA UAA200913938A patent/UA97400C2/uk unknown
- 2008-06-20 KR KR1020097027543A patent/KR101230085B1/ko not_active Expired - Fee Related
- 2008-06-20 AR ARP080102668A patent/AR067112A1/es unknown
- 2008-06-20 JP JP2010514996A patent/JP5551589B2/ja not_active Expired - Fee Related
- 2008-06-20 EP EP08771559.5A patent/EP2173348B1/en active Active
- 2008-06-20 EA EA201201155A patent/EA023697B1/ru not_active IP Right Cessation
- 2008-06-20 US US12/664,664 patent/US8318713B2/en not_active Expired - Fee Related
- 2008-06-20 BR BRPI0813789-7A2A patent/BRPI0813789A2/pt not_active IP Right Cessation
- 2008-06-20 WO PCT/US2008/067614 patent/WO2009006043A2/en not_active Ceased
- 2008-06-20 CN CN2012101150238A patent/CN102772416A/zh active Pending
- 2008-06-20 CN CN2008800231969A patent/CN101743005B/zh not_active Expired - Fee Related
- 2008-06-20 MY MYPI20095640A patent/MY154472A/en unknown
- 2008-06-20 CA CA2691587A patent/CA2691587C/en not_active Expired - Fee Related
- 2008-06-20 ES ES08771559.5T patent/ES2561202T3/es active Active
- 2008-06-20 EA EA201070085A patent/EA018447B1/ru not_active IP Right Cessation
-
2009
- 2009-11-19 IL IL202237A patent/IL202237A/en not_active IP Right Cessation
- 2009-12-08 ZA ZA2009/08725A patent/ZA200908725B/en unknown
-
2010
- 2010-01-27 MA MA32562A patent/MA31677B1/fr unknown
-
2011
- 2011-12-02 CL CL2011003046A patent/CL2011003046A1/es unknown
-
2012
- 2012-03-01 IL IL218443A patent/IL218443A0/en unknown
- 2012-10-18 US US13/654,884 patent/US8648063B2/en not_active Expired - Fee Related
-
2014
- 2014-01-17 JP JP2014006560A patent/JP2014114297A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2008001848A1 (es) | Uso de 7-(2,5-dihidro-4-imidazolo[1,2-a]-piridin-3-il-2,5-dioxo-1h-pirrol-3-il)-9-fluoro-1,2,3,4-tetrahidro-2-(1-piperidinil-carbonil)pirrolo[3,2,1-jk][1,4]benzodiazepina en combiancion con un agente quimioterapeutico de un grupo definido para tratar cancer de ovario, de pulmon de celulas no peeeeeeeequenas y colorrectal. | |
| CL2011000116A1 (es) | Compuestos derivados de imidazo[1,2-a]piridina; procedimiento de preparacion; composicion farmaceutica; compuestos intermediarios; y uso en el tratamiento del cancer. | |
| IL196243A (en) | [4,2,1] Triazole [3,4– a Pyridine Derivatives | |
| CL2011000729A1 (es) | Compuestos derivados de metanopirazolo[3,4-e][1,3]diazepin; procedimiento de preparacion; composicion farmaceutica que los comprende; y su uso en el tratamiento de infecciones bacterianas. | |
| CL2011000119A1 (es) | Compuestos derivados de triazolo[4,3-a]piridina; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer. | |
| CL2008001745A1 (es) | Compuestos derivados de imidazo[1,2-a]pirazina; composición farmacéutica; y uso de los compuestos como inhibidores de la proteína quinasa en el tratamiento del cáncer. | |
| ECSP088425A (es) | INHIBIDORES DE LA ACTIVIDAD Akt | |
| JP2010532364A5 (OSRAM) | ||
| MX2011010937A (es) | Derivado benzodiazepina para el tratamiento de neoplasma hermatopoyetico y leucemia. | |
| CL2008001540A1 (es) | Compuestos derivados de pirrolopiridinas y pirazolopiridinas; composicion farmaceutica; y uso en el tratamiento del cancer. | |
| WO2009139921A3 (en) | Microorganisms for preventing and treating neoplasms accompanying cellular therapy | |
| CL2008002139A1 (es) | Compuestos dimeros derivados de pirrolo[2,1c][1.4]benzodiazepina- 5 -ona (tomaimicina), conjugado que los comprenden; procedimiento de preparacion de los conjugados; composicion farmaceutica que comprende a los compuestos o conjugados; y uso de los compuestos y de los conjugados en el tratamiento del cancer. | |
| CL2008002687A1 (es) | Uso de una combinacion farmaceutica de un compuesto derivado de tieno[3,2-d]pirimidina con un agente quimioterapeutico en el tratamiento de un trastorno hiperproliferativo; kit farmaceutico. | |
| PH12013500742A1 (en) | Imidazo[1,2-b]pyridazine and imidazo[4,5-b]pyridine derivatives as jak inhibitors | |
| CL2008003846A1 (es) | Uso de compuestos derivados de 1,2,4-triazolo condensado con heterociclos, los cuales actuan como ligados del receptor de androgeno (ar); compuestos; proceso de preparacion; composicion farmaceutica y el uso de dichos compuestos para el tratamiento del cancer de prostata. | |
| EA201591932A1 (ru) | ПРИМЕНЕНИЕ ЗАМЕЩЕННЫХ 2,3-ДИГИДРОИМИДАЗО[1,2-c]ХИНАЗОЛИНОВ ДЛЯ ЛЕЧЕНИЯ ЛИМФОМ | |
| CL2007001710A1 (es) | Compuestos derivados de amino-pirazolopiridina sustituidos; metodo de preparacion; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como tumores, artritis reumatoide, enfermedades de crecimiento vascular desregulado, entre otras. | |
| MX2009002995A (es) | Derivados de pirazolo-[1,5-a]-pirimidina y su uso terapeutico. | |
| IL214348A (en) | Use of (-) - trans – 3– (6,5 – dihydro-h4 – pyrrolo [1,2,3 ji] quinoline – 1 – il) –4– (h1– indole – 3 – il) –pyrrolidine – 5, 2 - Deion for the preparation of a drug for the treatment of cancer that is suitable for use with sorfiniv or arlotinib | |
| AR082691A1 (es) | Terapia de combinacion, producto farmaceutico, kit y uso | |
| WO2021080920A3 (en) | Combination therapy for the treatment of solid and hematological cancers | |
| EP2277884A8 (en) | Anthracycline antibiotic derivatives with high activity, preparation methods and uses thereof | |
| CL2007001795A1 (es) | Compuestos derivados de 4-oxo-1,2,8-triaza-espiro[4.5] decano, que actuan como inhibidores del canal de potasio kv1.5; composicion farmaceutica que los comprende; y uso de los compuestos en la prepararcion de medicamentos para tratar o prevenir arritmias cardiacas | |
| WO2009087091A8 (en) | Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy | |
| WO2022221834A3 (en) | Method for treating lung cancer and non-small cell lung cancer |